Literature DB >> 2558763

Pharmacological profile of leukotrienes E4, N-acetyl E4 and of four of their novel omega- and beta-oxidative metabolites in airways of guinea-pig and man in vitro.

M N Samhoun1, D M Conroy, P J Piper.   

Abstract

1, The biological effects of metabolites of leukotriene E4 (LTE4) i.e. N-acetyl LTE4 (N-AcLTE4), 20-COOH-LTE4, 20-COOH-N-AcLTE4, as well as 18-COOH-19,20-dinor-LTE4 (dinor-LTE4) and 16-COOH-17,18,19,20-tetranor-14,15-dihydro-LTE4 (tetranor-LTE4) were investigated on superfused strips of guinea-pig trachea (GPT) and lung parenchyma (GPP) in vitro. 2. The actions of LTE4 were studied in isolated, superfused strips of human lung parenchyma (HP) and bronchus (HBr), in comparison with LTD4 and histamine. Effects of N-AcLTE4, the 20-carboxy metabolites, dinor-LTE4 and tetranor-LTE4 were also investigated in HBr. 3. N-AcLTE4 (0.1-10 nmol) induced dose-related contractions of GPT and was approximately 100 times less active than LTD4 (3-100 pmol). 4. In GPP, N-AcLTE4 (0.01-3 nmol) was equiactive with LTE4 (0.01-1 nmol) and approximately one order of magnitude less active than LTD4 (1-300 pmol). Contractions caused by N-AcLTE4 and LTE4 were very similar and approximately twice as sustained as those due to LTD4. 5. LTE4 (0.1-30 nmol) contracted strips of HP and HBr and was about 2-3 orders of magnitude less active than LTD4. As in GPP, the effect of LTE4 was more protracted than that of LTD4. Actions of N-AcLTE4 were similar to those of LTE4 in HBr. 6. 20-carboxy-LTE4, 20-carboxy-N-AcLTE4, dinor-LTE4 and tetranor-LTE4, all at 0.3-30 nmol, were inactive in GPT, GPP and HBr. 7. Indomethacin (2.8 microM) potentiated the effect of N-AcLTE4 in GPT, inhibited its contraction in GPP but did not affect that due to LTE4 in either HP or HBr. FPL 55712 (1.9 microM) antagonised leukotriene-induced contractions in GPT, GPP and HBr. 8. In conclusion, the metabolism of LTD4 to LTE4 or N-AcLTE4 may represent a detoxification but not an inactivation of cysteinyl-containing leukotrienes, since both metabolites still retain considerable biological activity in guinea-pig and human airways in vitro. However, further metabolism of LTE4 and N-AcLTE4 appears to result in inactivation of leukotrienes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558763      PMCID: PMC1854826     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4.

Authors:  L Orning; L Kaijser; S Hammarström
Journal:  Biochem Biophys Res Commun       Date:  1985-07-16       Impact factor: 3.575

2.  Comparison of the actions of leukotriene E4 with those of leukotrienes B4, C4, and D4 on guinea pig lung and ileal smooth muscle in vitro.

Authors:  P J Piper; M N Samhoun
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1983

3.  The zig-zag tracheal strip.

Authors:  J Emmerson; D Mackay
Journal:  J Pharm Pharmacol       Date:  1979-11       Impact factor: 3.765

4.  Metabolism and analysis of cysteinyl leukotrienes in the monkey.

Authors:  C Denzlinger; A Guhlmann; P H Scheuber; D Wilker; D K Hammer; D Keppler
Journal:  J Biol Chem       Date:  1986-11-25       Impact factor: 5.157

5.  Metabolism of leukotriene E4 by rat tissues: formation of N-acetyl leukotriene E4.

Authors:  K Bernström; S Hammarström
Journal:  Arch Biochem Biophys       Date:  1986-02-01       Impact factor: 4.013

6.  Stimulation of arachidonic acid metabolism and generation of thromboxane A2 by leukotrienes B4, C4 and D4 in guinea-pig lung in vitro.

Authors:  P J Piper; M N Samhoun
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

7.  Identification of the major endogenous leukotriene metabolite in the bile of rats as N-acetyl leukotriene E4.

Authors:  W Hagmann; C Denzlinger; S Rapp; G Weckbecker; D Keppler
Journal:  Prostaglandins       Date:  1986-02

8.  Biliary and urinary excretion of peptide leukotrienes in the domestic pig.

Authors:  D Ezra; A Foster; M Cirino; J Rokach; L G Letts
Journal:  Prostaglandins       Date:  1987-05

9.  Synthesis of beta-oxidation products as potential leukotriene metabolites and their detection in bile of anesthetized rat.

Authors:  D Delorme; A Foster; Y Girard; J Rokach
Journal:  Prostaglandins       Date:  1988-09

10.  In vitro metabolism of [3H]-peptide leukotrienes in human and ferret lung: a comparison with the guinea pig.

Authors:  D Aharony; P T Dobson; R D Krell
Journal:  Biochem Biophys Res Commun       Date:  1985-09-16       Impact factor: 3.575

View more
  6 in total

Review 1.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders.

Authors:  E Mayatepek; W D Lehmann; J Fauler; D Tsikas; J C Frölich; R B Schutgens; R J Wanders; D Keppler
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

3.  The effect of epithelium removal on leukotriene E4-induced histamine hyperresponsiveness in guinea-pig tracheal smooth muscle.

Authors:  C A Jacques; B W Spur; M Johnson; T H Lee
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

Review 4.  Leukotrienes as a target in asthma therapy.

Authors:  N Chanarin; S L Johnston
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

5.  Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2.

Authors:  Luzheng Xue; Anna Barrow; Vicki M Fleming; Michael G Hunter; Graham Ogg; Paul Klenerman; Roy Pettipher
Journal:  J Immunol       Date:  2011-12-14       Impact factor: 5.422

6.  Lactobacillus rhamnosus GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice via gut-microbiota-dependent anti-inflammation.

Authors:  Hao Liu; Ranli Gu; Wei Li; Wen Zhou; Zhe Cong; Jing Xue; Yunsong Liu; Qiang Wei; Yongsheng Zhou
Journal:  Ther Adv Chronic Dis       Date:  2019-07-03       Impact factor: 5.091

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.